Unaudited Financial Statements

for the Year Ended 31st December 2018

for

Toxpath Sciences Ltd

Contents of the Financial Statements for the Year Ended 31st December 2018

	Page
Company Information	1
Abridged Balance Sheet	2
Notes to the Financial Statements	3

Toxpath Sciences Ltd

Company Information for the Year Ended 31st December 2018

DIRECTORS: Prof J R Foster

Mrs J Foster

REGISTERED OFFICE: 1 Troutbeck Avenue

Congleton Cheshire CW12 4JA

REGISTERED NUMBER: 08797772 (England and Wales)

Abridged Balance Sheet 31st December 2018

CHIRDENIE ACCETS	Notes	31/12/18 £	31/12/17 £
CURRENT ASSETS		5 041	20.515
Debtors		7,941	28,515
Cash at bank		39,933	<u>13,871</u>
		47,874	42,386
CREDITORS			
Amounts falling due within one year		<u>31,221</u>	33,174
NET CURRENT ASSETS		16,653	9,212
TOTAL ASSETS LESS CURRENT			
LIABILITIES		16,653	9,212
CAPITAL AND RESERVES			
Called up share capital		1	1
Retained earnings		16,652	9,211
-		16,653	9,212

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2018 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

statements, so far as applicable to the company.

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

All the members have consented to the preparation of an abridged Balance Sheet for the year ended 31st December 2018 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 14th May 2019 and were signed on its behalf by:

Prof J R Foster - Director

Notes to the Financial Statements for the Year Ended 31st December 2018

1. STATUTORY INFORMATION

Toxpath Sciences Ltd is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied and services rendered, stated net of discounts and of Value Added Tax.

Income is recognized when goods have been delivered to customers such that risks and rewards of ownership have transferred to them.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery etc - 50% on cost

Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.

Financial instruments

The following assets and liabilities are classified as financial instruments - trade debtors, trade creditors, and directors loans.

Directors loans (being repayable on demand), trade debtors and trade creditors are measured at the undiscounted amount of the cash or other consideration expected to be paid or received.

Financial assets that are measured at amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the statement of income and Retained Earnings.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Page 3 continued...

Notes to the Financial Statements - continued for the Year Ended 31st December 2018

3. TANGIBLE FIXED ASSETS

TANGIBLE FIAED ASSETS	Totals £
COST	
At 1st January 2018	
and 31st December 2018	<u>2,131</u>
DEPRECIATION	
At 1st January 2018	
and 31st December 2018	2,131
NET BOOK VALUE	
At 31st December 2018	
At 31st December 2017	<u> </u>

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.